ReviewFrontiers in physiology2025
Beyond structural domains: the emerging roles of PDLIM2 in cellular signaling and cancer progression.
Review in Frontiers in physiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Proteomic and machine learning analysis predicts treatment response signatures in Myasthenia Gravis.Journal of translational medicine · 2026Trial
- PDLIM2 acts as a central regulator of ubiquitination, immune signaling, and mitochondrial metabolism in lung cancer suppression (Review).International journal of oncology · 2026Review
- Proteomic and Machine Learning Analysis Predicts Treatment Response Signatures in Myasthenia Gravis.Research square · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The cytoskeleton not only provides structural support for cells but also plays a crucial role in intracellular information transmission. Cytoskeleton-associated proteins are intricately involved in, and indispensable for, regulating cytoskeletal dynamics. PDLIM2, also known as mystique or SLIM, is localized in the nucleus and cytoplasm and functions as a cytoskeleton-associated protein that facilitates binding of other proteins to the cytoskeleton. PDLIM2 exhibits widespread expression in various tissues and cell types, contributing to cellular proliferation and differentiation processes. This review provides a concise overview of PDLIM2, including its genetic background, structural features, involvement in tumorigenesis and development, as well as potential molecular signaling pathways. Lastly, we address the current limitations in PDLIM2 research while highlighting future prospects.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.